What is ORIC Pharmaceuticals, Inc.'s (ORIC) StockRank?

MoatMap's StockRank for ORIC Pharmaceuticals, Inc. (ORIC) is 21/100, with a Sell signal. This is a composite score combining Quality (40), Value (39), and Momentum (32) factor ranks across MoatMap's 19,000+ stock universe.

Does ORIC Pharmaceuticals, Inc. have an economic moat?

ORIC Pharmaceuticals, Inc. (ORIC) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is ORIC Pharmaceuticals, Inc. a buy, hold, or sell?

MoatMap's current signal for ORIC Pharmaceuticals, Inc. (ORIC) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is ORIC Pharmaceuticals, Inc. in?

ORIC Pharmaceuticals, Inc. (ORIC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ORIC

SELLREMOVE

ORIC Pharmaceuticals, Inc. · Healthcare · United States · $875M · Avg Vol: $14M/d

StockRank

P/E (TTM)

—

ROE

-42.6%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

ORIC Pharmaceuticals is a clinical-stage oncology biotech. It lacks owner earnings, pricing power, or a proven commercial moat, failing our fundamental quality screens.

COMPANY DESCRIPTION

ORIC Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies that overcome resistance in cancer. The company targets critical mechanisms of therapeutic resistance in oncology, addressing a significant unmet medical need through its proprietary pipeline. ORIC is a specialized oncology biotech firm, aiming to develop first-in-class or best-in-class treatments by precisely targeting cancer resistance pathways.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0	0	0	0	—
EPS	-2.07	-2.25	-1.96	-1.83	—	—
Shares	—	45M	55M	71M	99M	+118.5%
Debt	—	3M	3M	3M	3M	7.8%
Equity	—	222M	224M	243M	384M	20.0%
Op CF	—	-75M	-86M	-113M	-111M	—
Inv CF	—	-109M	-43M	22M	-148M	—
Fin CF	—	25M	86M	127M	245M	—

PRICE (1M)-12.8%

SMA 50SMA 200

$8.40

RSI (14)

48.5

52W High

$14.93

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-36.8%18.9

ROE

-42.6%20.0

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-16.6%20.3

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.02x84.5

Current Ratio

16.33x93.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-3.9x70.9

P/FCF

—N/A

P/B

2.1x54.5

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

56%33.5

RS 6M

-22%53.3

SMA 50/200

0.84x20.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-13%16.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$875M

P/E (Forward)

-5.3x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORIC are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ORIC	ORIC Pharmaceuticals, Inc.(you)	$875M	21	SELL
CTMX	CytomX Therapeutics, Inc.	$808M	21	SELL
KURA	Kura Oncology, Inc.	$885M	19	STRONG SELL
VOR	Vor Biopharma Inc.	$813M	23	SELL
DRUG.CN	Bright Minds Biosciences Inc.	$873M	18	STRONG SELL
AVTX	Avalo Therapeutics, Inc.	$848M	17	STRONG SELL
XNCR	Xencor, Inc.	$887M	16	STRONG SELL
JANX	Janux Therapeutics, Inc.	$899M	15	STRONG SELL
ANNX	Annexon, Inc.	$880M	27	SELL
EVMN	Evommune, Inc.	$840M	15	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

ORIC Pharmaceuticals, Inc. (ORIC) — Stock Score Summary

ORIC Pharmaceuticals, Inc. (ORIC) has a MoatMap StockRank of 21/100 based on Quality (40/100), Value (39/100), and Momentum (32/100) factor scores. The current signal is SELL. ORIC Pharmaceuticals is a clinical-stage oncology biotech. It lacks owner earnings, pricing power, or a proven commercial moat, failing our fundamental quality screens.

Key Financial Metrics

Price	$8.40
Market Cap	$875M
P/E (Forward)	-5.25
Price/Book	2.06
Return on Equity	-42.6%
Return on Invested Capital	-36.8%
Debt/Equity	1.62
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-68M

ORIC Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is ORIC Pharmaceuticals, Inc.’s (ORIC) StockRank?: MoatMap’s StockRank for ORIC Pharmaceuticals, Inc. (ORIC) is 21/100, with a Sell signal. It is a composite of Quality (40), Value (39), and Momentum (32) factor ranks across MoatMap’s 19,000+ stock universe.
Does ORIC Pharmaceuticals, Inc. have an economic moat?: ORIC Pharmaceuticals, Inc. (ORIC) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is ORIC Pharmaceuticals, Inc. a buy, hold, or sell?: MoatMap’s current signal for ORIC Pharmaceuticals, Inc. (ORIC) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is ORIC Pharmaceuticals, Inc. in?: ORIC Pharmaceuticals, Inc. (ORIC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).